+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

P

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the immune response and safety of a new combined vaccine that protects against diphtheria, tetanus, and whooping cough in infants and young children aged 2 to 3 months. This Phase III clinical trial aims to compare the effects of an adsorption-free version of this vaccine with other combined vaccines to understand how well it protects against these diseases. The importance of this research lies in preventing these serious infections in early childhood. The study involves three groups receiving different vaccine formulations DTacP, DTaP, and DTacP-IPVHib. Each group will get injections at 2 months, 4 months, 6 months, 18 to 24 months, and some at 6 years of age, with doses of 0.5 ml administered by injection. The DTacP-IPVHib group receives doses up to 18 months of age. These vaccinations are given to see how each vaccine performs over time in building immunity. Participants will be monitored for immune response 30 days after the primary immunization and after booster doses. Safety will also be tracked up to 12 months after completing the full vaccination series. Throughout the study, infants and young children will have vaccination visits, health assessments, and follow-ups to ensure data is collected on how their bodies respond to the vaccines and to monitor for any side effects. The total participation spans several years with multiple immunization points and safety checks.

Age: 2Months - 3MonthsAll GendersPhase 3
1 location
E

Actively Recruiting

Stroke is one of the leading causes of death worldwide, with ischemic stroke being the most common type. Researchers are evaluating whether early administration of oral aspirin after intravenous thrombolysis improves functional outcomes for patients with acute ischemic stroke. The study aims to determine if starting aspirin treatment within 3 hours of thrombolysis can prevent neurological deterioration without increasing bleeding risks. Participants are randomly assigned to one of two groups the interventional group receives 300 mg of oral aspirin shortly after starting intravenous thrombolysis, while the control group receives a placebo. Both groups receive the best standard medical care according to current guidelines. Aspirin tablets may be chewed or given via a nasogastric tube if swallowing is difficult. The treatment is administered within 3 hours of initiating thrombolysis. During the study, participants are monitored for neurological improvements and potential complications using scales like the modified Rankin scale and NIH Stroke Scale at various time points up to 90 days after stroke. Researchers will assess functional outcomes, neurological changes, and safety measures, including the risk of intracranial hemorrhage. The total follow-up period extends to 90 days post-stroke.

Age: 18Years +All GendersPhase 3
119 locations